Black Diamond Therapeutics, Inc. (BDTX)

BDTX Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	21.5	-69.68	-82.44	-91.17	-125.6	-67.25
Depreciation & Amortization	0.34	0.34	0.44	0.51	0.21	0.05
Loss (Gain) From Sale of Assets	-0.03	-0.09	0.36	-2.23	0	-
Loss (Gain) From Sale of Investments	-1.86	-3.78	-1.17	0.54	2.18	1.7
Loss (Gain) on Equity Investments	-	-	-	2.25	-	-
Stock-Based Compensation	6.85	10.63	9.6	12.2	14.04	7.77
Other Operating Activities	3.1	2.97	2.81	2.73	2.01	0.55
Change in Accounts Payable	-1	1.68	0.6	-2.23	1.57	1.07
Change in Other Net Operating Assets	-7.56	-4.38	3.09	-7.67	5.45	3.97
Operating Cash Flow	21.35	-62.3	-66.72	-85.08	-100.15	-52.15
Capital Expenditures	-	-	-0.03	-0.19	-2.71	-0.14
Sale of Property, Plant & Equipment	0.03	0.09	0.1	0.01	-	-
Investment in Securities	-14.28	16.87	16.28	53.55	133.32	-281.55
Investing Cash Flow	-14.25	16.97	16.35	53.37	130.61	-281.69
Issuance of Common Stock	0.34	25.55	71.93	0.18	0.73	216.22
Other Financing Activities	-	-	-	-	-	-1.28
Financing Cash Flow	0.34	25.55	71.93	0.18	0.73	214.94
Net Cash Flow	7.44	-19.79	21.56	-31.54	31.19	-118.89
Free Cash Flow	21.35	-62.3	-66.75	-85.27	-102.86	-52.29
Free Cash Flow Per Share	0.37	-1.13	-1.52	-2.35	-2.84	-1.59
Levered Free Cash Flow	10.25	-35.76	-37.65	-55.39	-59.04	-30.94
Unlevered Free Cash Flow	10.25	-35.76	-37.65	-55.39	-59.04	-30.94
Change in Working Capital	-8.56	-2.69	3.69	-9.9	7.02	5.04

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q